[HTML][HTML] European Reference Network for Rare Vascular Diseases (VASCERN): When and how to use intravenous bevacizumab in hereditary haemorrhagic …
S Dupuis-Girod, CL Shovlin, AD Kjeldsen… - European Journal of …, 2022 - Elsevier
Hereditary haemorrhagic telangiectasia (HHT) is a rare vascular multisystemic disease that
leads to epistaxis, anaemia due to blood loss, and arteriovenous malformations (AVMs) in
organs such as the lungs, liver and brain. HHT prevalence is estimated at 1/6000, ie around
85,000 European citizens, and is served by the European Reference Network for Rare
Multisystemic Vascular Diseases (VASCERN). HHT treatments depend on clinical
manifestations, and span multiple different medical, surgical and interventional disciplines …
leads to epistaxis, anaemia due to blood loss, and arteriovenous malformations (AVMs) in
organs such as the lungs, liver and brain. HHT prevalence is estimated at 1/6000, ie around
85,000 European citizens, and is served by the European Reference Network for Rare
Multisystemic Vascular Diseases (VASCERN). HHT treatments depend on clinical
manifestations, and span multiple different medical, surgical and interventional disciplines …